Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine

• Published in: Clinical pharmacokinetics Vol. 60; no. 6; pp. 819 - 828
• Main Authors: Tsai, Max, Nery, Emel Serap Monkul, Kerr, Lisa, Khanna, Rashna, Komori, Mika, Dennehy, Ellen B., Wilbraham, Darren, Winner, Paul
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2021; Springer Nature B.V
• Subjects: Adolescent; Adults; Benzamides; Child; Cohort Studies; Double-Blind Method; Drug dosages; Headaches; Humans; Internal Medicine; Laboratories; Medicine; Medicine & Public Health; Migraine; Migraine Disorders - drug therapy; Original; Original Research Article; Patients; Pediatrics; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Piperidines; Pyridines; Serotonin Receptor Agonists; Treatment Outcome

Introduction Lasmiditan is a selective serotonin (5-HT1F) receptor agonist approved in the US for the acute treatment ofmigraine in adults. This phase I, open-label, two-cohort study assessed the pharmacokinetics (PK), safety, and tolerability of lasmiditan in patients with migraine aged 6 to < 1...